Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Permeability' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Permeability' found in 1 term [] and 14 definitions []
1 - 5 (of 15)     next
Result Pages : [1]  [2 3]
Searchterm 'Permeability' was also found in the following services: 
spacer
Forum  (1)  
 
Permeability
 
(m) Tendency of a substance to concentrate magnetic field, m = B/H.
spacer
 
• Share the entry 'Permeability':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Permeability' (1).Open this link in a new window.
 
Further Reading:
  News & More:
MICRO-STRUCTURAL QUANTITIES - DIFFUSION, MAGNETISATION DECAY, MAGNETISATION TRANSFER AND PERMEABILITY(.pdf)
   by www.dundee.ac.uk    
Magnetic resonance-guided motorized transcranial ultrasound system for blood-brain barrier permeabilization along arbitrary trajectories in rodents
Thursday, 24 December 2015   by www.ncbi.nlm.nih.gov    
Quantitative MRI may differentiate true from pseudoprogression in glioblastoma
Saturday, 25 October 2014   by www.2minutemedicine.com    
Searchterm 'Permeability' was also found in the following services: 
spacer
Radiology  (3) Open this link in a new windowUltrasound  (1) Open this link in a new window
Magnetic Shielding
 
Means to confine the region of strong magnetic field surrounding a magnet;; most commonly the use of material with high permeability (passive shielding) or by employing secondary counteracting coils outside of the primary coils (active shielding). The high permeability material can be employed in the form of a yoke immediately surrounding the magnet (self-shielding) or installed in the walls of a room as full or partial room-shielding. Unlike shielding ionizing radiation, for example, magnetic shielding can only be accomplished by forcing the unavoidable magnetic return flux through more confined areas or structures, not by absorbing it.
See also Radio Frequency Shielding Radio Frequency Shielding, and Faraday cage.

See also the related poll result: 'Most outages of your scanning system are caused by failure of'
spacer

• View the DATABASE results for 'Magnetic Shielding' (11).Open this link in a new window

 
Further Reading:
  Basics:
Faraday's Law
   by hyperphysics.phy-astr.gsu.edu    
  News & More:
Magnetic Sensitivity of MRI Systems to External Iron: The Design Process
   by www.integratedsoft.com    
MRI Resources 
Shielding - Image Quality - Cardiovascular Imaging - Process Analysis - MR Guided Interventions - Resources
 
NC100150 InjectionInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™(1)
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection is discontinued.


1. IMPORTANT: The trade name Clariscan™ planned to be used at the time of Amersham Health is reused (since 2017) for a contrast agent developed by GE Healthcare. The newly developed Clariscan™ by GE Healthcare is a totally different contrast agent with first approvals in March of 2017. Please read Clariscan™.
spacer

• View the DATABASE results for 'NC100150 Injection' (5).Open this link in a new window


• View the NEWS results for 'NC100150 Injection' (2).Open this link in a new window.
Searchterm 'Permeability' was also found in the following services: 
spacer
Forum  (1)  
 
Breast MRIMRI Resource Directory:
 - Breast MRI -
 
(MR mammography) Magnetic resonance imaging of the breast is particularly useful in evaluation of newly diagnosed breast cancer, in women whose breast tissue is mammographically very dense and for screening in women with a high lifetime risk of breast cancer because of their family history or genetic disposition.
Breast MRI can be performed on all standard whole body magnets at a field strength of 0.5 T - 1.5 Tesla. Powerful gradient strengths over 15 mT/m will help to improve the balance between spatial resolution, scanning speed, and volume coverage. The use of a dedicated bilateral breast coil is obligatory.
Malignant lesions release angiogenic factors that increase local vessel density and vessel permeability. Breast cancer is detectable due to the strong enhancement in dynamic breast imaging that peaks early (about 1-2 min.) after contrast medium injection. If breast cancer is suspected, a breast biopsy may be necessary to secure the diagnosis.
See also Magnetic Resonance Imaging MRI, Biopsy and MR Guided Interventions.

Requirements in breast MRI procedures:
Both breasts must be measured without gaps.
Temporal resolution should be sufficient to allow early imaging after contrast agent with dynamic imaging every 60-120 sec.
For the best possible detection of enhancement fat signal should be eliminated either by image subtraction or by spectrally selective fat saturation.
Thin slices are necessary to assure absence of partial volume effects.
Imaging should be performed with a spatial resolution in plane less than 1 mm.


For Ultrasound Imaging (USI) see Breast Ultrasound at US-TIP.com.

See also the related poll result: 'MRI will have replaced 50% of x-ray exams by'
 
Images, Movies, Sliders:
 Breast MRI Images T2 And T1  Open this link in a new window
      
 Breast MRI Images T2 And T1 Pre - Post Contrast  Open this link in a new window
 Breast MRI Images T1 Pre - Post Contrast  Open this link in a new window
      
 
Radiology-tip.comMammography,  Breast Imaging
spacer
Radiology-tip.comBreast Ultrasound
spacer

• View the DATABASE results for 'Breast MRI' (13).Open this link in a new window


• View the NEWS results for 'Breast MRI' (41).Open this link in a new window.
 
Further Reading:
  Basics:
New Screening Guidelines for Women at High Risk for Breast Cancer
Wednesday, 26 September 2007   by www.newswise.com    
CONTRAST-ENHANCED MRI OF THE BREAST(.pdf)
MRI Improves Breast Cancer Screening in Older BRCA Carriers
Monday, 5 January 2015   by www.cancernetwork.com    
  News & More:
Researchers to develop new hybrid PET/MRI system for improved breast cancer diagnosis
Wednesday, 27 January 2016   by cordis.europa.eu    
Additional Breast Cancer Tumors Found on MRI After Mammography May Be Larger, More Aggressive
Wednesday, 9 December 2015   by www.oncologynurseadvisor.com    
Preoperative MRI May Overdiagnose Contralateral Breast Cancer
Wednesday, 2 December 2015   by www.cancertherapyadvisor.com    
MRI Better Detects Recurrent Breast Cancer
Friday, 15 August 2014   by www.doctorslounge.com    
7-Tesla MRI scanner allows even more accurate diagnosis of breast cancer
Thursday, 6 March 2014   by www.healthcanal.com    
BI-RADS and breast MRI useful in predicting malignancy
Wednesday, 30 May 2012   by www.oncologynurseadvisor.com    
Searchterm 'Permeability' was also found in the following services: 
spacer
Radiology  (3) Open this link in a new windowUltrasound  (1) Open this link in a new window
Clariscan™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Clariscan™ (gadoteric acid), a macrocyclic and ionic gadolinium-based contrast agent has newly been approved using the decentralized procedure with marketing authorization in place in Norway. It will be introduced by GE Healthcare to European countries in 2017.


See also: Paramagnetic Contrast Agents, Contrast Medium, Extracellular Fluid Agents, Ionic Intravenous Contrast Agents, Nonionic Intravenous Contrast Agents, Chelate, Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'

Drug Information and Specification
NAME OF COMPOUND Gadoteric Acid
DEVELOPER GE Healthcare
CENTRAL MOIETY Gadolinium
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY R1 3.1, R2 3.6, B0 = 1.5 Tesla
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mOsm.kg-1
CONCENTRATION 0.5 mmol /mL
DOSAGE 0.1 mmol/kg / 0.2 ml/kg
INDICATION Brain, spine and associated tissues
PRESENTATIONS Glass vial 5, 10, 15, 20 mL
Glass bottle 50, 100 mL
Polypropylene bottles 50, 100 mL
Plastic (Crystal Clear Polymer) pre-filled syringes 10, 15, 20 mL
DEVELOPMENT STAGE Sale starts 2017 in Norway, Sweden, UK. Global launch is planned.
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT


[ Clariscan™ was also the name of an contrast agent under development by Amersham Health around the year 2000 which doesn't reach the market: '(An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and was developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours. See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide)'.
The new developed Clariscan™ by GE Healthcare is a totally different contrast agent.]
spacer

• View the DATABASE results for 'Clariscan™' (6).Open this link in a new window

 
Further Reading:
  Basics:
SUMMARY OF PRODUCT CHARACTERISTICS
Wednesday, 22 February 2017   by www.mhra.gov.uk    
  News & More:
GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
Wednesday, 1 March 2017   by www.businesswire.com    
MRI Resources 
Pathology - Education - Pacemaker - Veterinary MRI - Service and Support - Spine MRI
 
     1 - 5 (of 15)     next
Result Pages : [1]  [2 3]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



In 2020 your scanner will probably work with a field strength of :
lower 
1T 
1.5T 
2T 
3T 
7T 
higher 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 15 August 2018]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]